Q’Apel Medical has announced that it has received CE-mark certification for its Armadillo SelectFlex neurovascular access system. As noted in a company press release, this “first-of-its-kind” 7Fr system features the patented SelectFlex technology and is indicated for the introduction of interventional devices into the neurovasculature.
“Neurovascular access can be extremely challenging. The tortuous anatomy requires flexibility to navigate the tight twists and turns; however, flexible access catheters tend to lack the support and stability required for device delivery once positioned,” said Pascal Jabbour (Thomas Jefferson University Hospital, Philadelphia, USA). “Armadillo provides a one-and-done solution that simplifies access procedures. It is designed to place full control in the hands of the operator as it allows users to transform the catheter from highly trackable to highly supportive as needed throughout the procedure with the simple injection or withdrawal of just 0.2cc of saline.”
The release goes on to state that the Armadillo neurovascular access system with SelectFlex technology delivers the versatility required for physicians to confidently tackle a wide range of neurovascular interventions. And, regardless of access site, the low-profile 7Fr catheter enables a biaxial approach to accelerate delicate interventions, and eliminate the complexity and cost of conventional triaxial configurations, Q’Apel claims.
“The Armadillo neurovascular access system with SelectFlex technology addresses the shortcomings of currently available neurovascular access catheters. We believe it provides a novel option that allows hospitals to standardise device usage, decrease inventory constraints and reduce cost per procedure,” added Jodie Fam, chief executive officer (CEO) of Q’Apel. “I thank our incredible team for their efforts to achieve this critical milestone. We look forward to building upon Armadillo’s US commercial success as we prepare to expand our international portfolio and deliver this meaningful solution to the European market, and others, in the coming months.”
